Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder

MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures announced today that it has enrolled the first subject in a Phase 1 exploratory study of the company’s first-in-class SIRT6 activator, SP-624, in healthy volunteers and patients with major depressive disorder (MDD). The study is designed to evaluate the impact of the epigenetic mechanism of action of SP-624, on neurological pathways and assess changes in various cognitive domains. SP-624 is also currently being studied in a large Phase 2b s